CymaBay Therapeutics (NASDAQ:CBAY) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of CymaBay Therapeutics (NASDAQ:CBAY – Free Report) in a report published on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued research reports about the company. William Blair cut CymaBay Therapeutics from an outperform rating to a market perform […]

Related Keywords

Raymond James ,Janet Dorling ,William Blair ,Cantor Fitzgerald ,Emerald Advisers ,Securities Exchange Commission ,Raymond James Financial Services Advisors Inc ,Strategic Blueprint ,Cymabay Therapeutics Inc ,Raymond James Associates ,Sg Americas Securities ,Cymabay Therapeutics ,Free Report ,Lifesci Capital ,Bay Therapeutics ,Get Free Report ,Director Janet Dorling ,Exchange Commission ,James Financial Services Advisors ,Cymabay Therapeutics Daily ,Nasdaq Cbay ,Cbay ,Medical ,Initiated Coverage ,Stocknews Com ,